Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 1,236 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,236 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $20.30, for a total value of $25,090.80. Following the completion of the sale, the insider now owns 77,099 shares in the company, valued at approximately $1,565,109.70. This represents a 1.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Castle Biosciences Stock Performance

NASDAQ CSTL traded down $0.24 during trading on Tuesday, reaching $19.78. The company's stock had a trading volume of 244,269 shares, compared to its average volume of 369,739. The business's fifty day moving average price is $24.10 and its 200-day moving average price is $27.90. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The firm has a market cap of $553.98 million, a price-to-earnings ratio of 98.90 and a beta of 0.98.

Wall Street Analysts Forecast Growth

CSTL has been the subject of a number of research analyst reports. Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a "buy" rating in a report on Friday. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Finally, Robert W. Baird lifted their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $38.75.

Institutional Trading of Castle Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of Castle Biosciences by 310.7% during the third quarter. Barclays PLC now owns 52,301 shares of the company's stock worth $1,491,000 after purchasing an additional 39,567 shares during the last quarter. JPMorgan Chase & Co. raised its position in Castle Biosciences by 165.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock worth $1,980,000 after buying an additional 43,241 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Castle Biosciences by 16.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company's stock worth $7,836,000 after acquiring an additional 39,417 shares during the period. Geode Capital Management LLC increased its stake in shares of Castle Biosciences by 1.1% during the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company's stock worth $17,820,000 after acquiring an additional 7,004 shares during the period. Finally, State Street Corp raised its holdings in Castle Biosciences by 9.8% during the third quarter. State Street Corp now owns 680,001 shares of the company's stock worth $19,394,000 after purchasing an additional 60,924 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.